Seres Therapeutics, Inc.

Hello, my name is Chris and I'll be your conference operator today. At this time, I'd like to welcome everyone to the Q1 2023 series therapeutics earnings conference call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question during this time, simply press star, then the number one on your telephone keypad. To withdraw your question, please press star 1 again. Thank you. Dr. Carlos Tanzi, Investor Relations. You may begin.

Thank you and good morning. Our press release for the company's first quarter 2023 financial results in the business update became available at 7 a.m. Eastern time this morning and can be found in the investors and news section of the company's website. We will also be reviewing new year 155 Phase 1B study results, and we have posted slides on our corporate website that will accompany our remarks. I'd like to remind you that we'll be making forward-looking statements, including the timing of commercial launch, the availability of VAUST, the commercial success of VAUST, the timing and results of clinical studies, the timing of additional clinical data, final study results, the ability for microbiome therapeutics to modulate for microbiome and treat or prevent infection, our ability to achieve certain sales targets and the receipt of future milestones and debt tranches, and other statements which are not historical fact. Actual results may differ materially. Additionally, these statements are subject to certain risks and uncertainties which are discussed under the risk factors section of our recent SEC filings. Any forward-looking statements made on today's call represent our views as of today only. We may update these statements in the future, but we disclaim any obligation to do so. On today's call, with prepared remarks, I'm joined by Eric Schaaf, series president and CEO, David Arkowitz, chief financial officer, Dr. Lisa Von Mulkey, chief medical officer, and Dr. Matthew Henn, chief scientific officer. Additionally, Dr. Terry Young, chief commercial officer, and Dr. Dave Agee, chief technology officer, will also be available to answer your questions.

And with that, I'll pass the call to Eric. Thank you, Carlo, and good morning, everyone.